Status:
RECRUITING
Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions:
Anti-Infective Agent
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Ceftazidime/avibactam (CAZ/AVI) is a new β-lactam drug, which has good antibacterial effect against carbapenem resistant enterobacter. However, previous studies found that CAZ/AVI had a low PK/PD comp...
Detailed Description
1. Main purpose The main objective of this study was to verify that the clinical efficacy of treatment group (load dose of 2.5g, then continuous infusion of 2.5gQ8h, the dose can be adjusted according...
Eligibility Criteria
Inclusion
- Multiple-resistant negative bacteria Sensitive to ceftazidime/avibactam Received intravenous infusion of ceftazidime/avibactam
Exclusion
- Allergic to ceftazidime/avibactam Blood sample not be collected Pregnant or lactating
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2025
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06528028
Start Date
July 1 2024
End Date
July 30 2025
Last Update
July 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intensive Care Unit, Drum Tower Hospital
Nanjing, Jiangsu, China, 210009